Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
India in the Changing Landscape of Life-Sciences Research & Development
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
Subscribe To Our Newsletter & Stay Updated
